List of Excipients in Branded Drug XALATAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
PFIZER LABORATORIES DIV PFIZER INC	XALATAN	latanoprost	0013-8303	BENZALKONIUM CHLORIDE
PFIZER LABORATORIES DIV PFIZER INC	XALATAN	latanoprost	0013-8303	SODIUM CHLORIDE
PFIZER LABORATORIES DIV PFIZER INC	XALATAN	latanoprost	0013-8303	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
PFIZER LABORATORIES DIV PFIZER INC	XALATAN	latanoprost	0013-8303	WATER
Viatris Specialty LLC	XALATAN	latanoprost	58151-419	SODIUM CHLORIDE
Viatris Specialty LLC	XALATAN	latanoprost	58151-419	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS

Xalatan Excipient Strategy and Commercial Opportunities in Latanoprost Ophthalmic Products

Last updated: August 29, 2026

Xalatan is a mature latanoprost ophthalmic solution whose core formulation is commercially proven but no longer protected by meaningful U.S. exclusivity. The product uses a simple aqueous system containing benzalkonium chloride, phosphate buffer, sodium chloride, and water. The strongest commercial opportunities are preservative-free delivery, improved multidose packaging, longer in-use stability, lower-cost manufacturing, and differentiated products for patients with ocular-surface disease.

What is the Xalatan formulation and which excipients does it contain?

Xalatan contains latanoprost at 0.005%, equivalent to 50 micrograms per milliliter. The formulation is an aqueous sterile ophthalmic solution with benzalkonium chloride as the preservative and phosphate salts used for buffering. Sodium chloride supports tonicity, and purified water is the vehicle. The labeled pH is approximately 6.7.[1]

Component	Function in Xalatan	Commercial relevance
Latanoprost	Prostaglandin F2α analog active ingredient	Highly potent; permits low drug loading
Benzalkonium chloride, 0.02%	Preservative and antimicrobial protection	Supports multidose packaging but creates ocular-surface tolerability concerns
Sodium chloride	Tonicity adjustment	Low-cost, conventional excipient
Sodium phosphate monobasic	Buffer component	Maintains formulation pH
Sodium phosphate dibasic	Buffer component	Supports pH control and stability
Water for injection or purified aqueous vehicle	Solvent	Requires sterile manufacturing and container-closure control

The formulation does not depend on a complex solubilizer system. This favors low-cost generic production, but it limits differentiation based on conventional excipient substitution.

Why is benzalkonium chloride important in Xalatan?

Benzalkonium chloride, commonly abbreviated BAK, allows Xalatan to be supplied in a multidose bottle without aseptic single-use dosing for every administration. It also creates a major product-development constraint.

Chronic exposure to BAK has been associated with ocular-surface irritation, tear-film disruption, epithelial effects, and reduced tolerability in patients receiving long-term glaucoma therapy. These concerns are commercially important because glaucoma patients often use treatment for years and may receive multiple topical medicines that contain BAK.[2]

The formulation therefore reflects a trade-off:

• BAK improves multidose microbial protection.
• BAK can reduce tolerability in chronic users.
• Removing BAK increases packaging, sterility, and preservative-validation requirements.
• A preservative-free product can command a price premium if it demonstrates improved comfort, adherence, or ocular-surface outcomes.

What patents protect Xalatan and when did latanoprost lose exclusivity?

Xalatan's original U.S. compound and product protection has expired. The product is now exposed to generic latanoprost competition, and FDA-approved generic versions have been available for many years.[3]

Protection category	Xalatan status	Commercial effect
Latanoprost active ingredient	Expired in the United States	No current compound-based barrier to generic entry
Original Xalatan formulation	Expired or no longer commercially blocking	Conventional generic solutions can compete
FDA regulatory exclusivity	Expired	No remaining brand exclusivity advantage
Orange Book patent protection	No meaningful current barrier to standard generic entry	Competition is primarily based on price, supply, quality, and contracting
New preservative-free or delivery-system claims	Potentially protectable if novel and non-obvious	Main route for new intellectual-property value

The relevant patent opportunity is no longer the basic latanoprost molecule. It is a differentiated formulation, delivery device, packaging configuration, manufacturing process, or treatment method that produces a measurable clinical or commercial advantage.

What is the Orange Book status of Xalatan?

The FDA Orange Book identifies approved drug products and, where applicable, patent and exclusivity information. The standard latanoprost market is a multisource generic market rather than a patent-blocked brand market.[3]

An Orange Book review should distinguish among:

1. The original Xalatan reference-listed drug.
2. Generic latanoprost ophthalmic solutions approved through abbreviated new drug applications.
3. New drug applications for preservative-free, fixed-dose, or device-enabled latanoprost products.
4. Any later-listed formulation or method-of-use patents.

The absence of an active basic-product patent does not prevent a new formulation sponsor from obtaining patents. It does mean that a new patent must protect a specific technical improvement rather than the ordinary latanoprost solution.

How strong is the Xalatan patent estate?

The legacy Xalatan patent estate is commercially weak for blocking standard generic solutions because the key exclusivity periods have ended. A new entrant would face greater risk from formulation patents only if it copies a protected preservative-free system, delivery device, manufacturing process, or combination product.

What patent claims could protect a next-generation latanoprost product?

Potentially valuable claims include:

• Preservative-free multidose containers with validated microbial protection.
• Low-BAK or alternative-preservative formulations.
• Latanoprost formulations with enhanced chemical stability.
• Reduced-degradation compositions that limit impurities during storage.
• Novel pH or buffer systems that improve comfort or shelf life.
• Low-volume or metered-dose delivery systems.
• Unit-dose packaging with improved oxygen and moisture barriers.
• Combination products containing latanoprost and another glaucoma active.
• Formulations designed for patients with ocular-surface disease.
• Manufacturing processes that reduce particulate contamination or degradation.

The strongest patents would connect the excipient choice or package design to measurable performance, such as longer in-use stability, lower preservative exposure, improved dose uniformity, or reduced ocular irritation.

What formulation opportunities exist beyond conventional Xalatan?

Preservative-free latanoprost

Preservative-free latanoprost is the clearest commercial opportunity. The product can be delivered in unit-dose vials, preservative-free multidose bottles, or proprietary metered-dose systems.

Unit-dose packaging has the simplest preservative logic because each container is discarded after use. Its disadvantages are higher packaging cost, greater material consumption, more complicated logistics, and potential patient inconvenience.

Preservative-free multidose packaging is commercially more attractive but technically harder. The container must prevent microbial ingress during repeated use, preserve dose accuracy, and maintain sterility or microbiological quality throughout the labeled in-use period.

Alternative preservatives

A sponsor could evaluate polyquaternium-1, stabilized oxychloro complexes, sorbic acid, or other preservative systems. Each substitution creates a regulatory and development burden. The alternative must demonstrate:

• Antimicrobial effectiveness.
• Compatibility with latanoprost.
• Chemical stability.
• Ocular tolerability.
• Container-closure compatibility.
• Acceptable extractables and leachables.
• Consistent delivery through the intended bottle or device.

An alternative preservative is not automatically superior to BAK. The commercial case requires evidence that the change improves patient experience or treatment persistence without compromising shelf life or manufacturing robustness.

Improved buffer and tonicity systems

The existing phosphate-buffered system is inexpensive and familiar. A different buffer may support improved comfort, reduced precipitation risk, or better stability under temperature excursions. However, a buffer change alone may have limited market value unless it produces a clinically relevant benefit or supports a clearly superior storage profile.

Sponsors should evaluate citrate, borate, tromethamine, and other ophthalmic buffer systems only after establishing a formulation target. The development objective could be lower irritation, improved pH stability, reduced degradation, or compatibility with a preservative-free package.

Solubility and stability enhancement

Latanoprost is administered at a very low concentration, so the product does not require the high drug loading associated with many poorly soluble medicines. The more important formulation challenge is chemical stability.

Potential development approaches include:

• Control of oxygen exposure.
• Lower headspace oxygen.
• Light-protective packaging.
• Antioxidant systems, where ophthalmically acceptable.
• Improved buffer selection.
• Reduced contact with reactive container materials.
• Cold-chain or controlled-temperature strategies.
• Lyophilized or reconstitutable presentations, although these would add patient and regulatory complexity.

A formulation that extends room-temperature stability could create value in emerging markets and retail channels where refrigeration is difficult.

What regulatory pathway applies to new Xalatan formulations?

A conventional generic latanoprost solution generally proceeds through an ANDA referencing the FDA-approved product. A materially different formulation, preservative system, dosage form, or delivery device may require a 505(b)(2) NDA rather than an ANDA.[4]

Product concept	Likely pathway	Main regulatory issue
Same active, strength, dosage form, and excipient profile	ANDA	Pharmaceutical equivalence and bioequivalence
Same latanoprost solution with minor excipient changes	Case-specific ANDA or 505(b)(2) assessment	Inactive-ingredient differences and equivalence
Preservative-free multidose system	Often 505(b)(2) or specialized ANDA strategy	Microbial protection, device performance, in-use stability
Unit-dose preservative-free latanoprost	505(b)(2) or ANDA depending on reference and formulation	Container configuration and comparative performance
New fixed-dose combination	505(b)(2) or 505(b)(1)	Combination-product clinical and CMC requirements
Novel delivery device	505(b)(2), NDA, or device-drug combination review	Dose uniformity, human factors, and device reliability

FDA ophthalmic guidance places substantial emphasis on sterility assurance, particulate matter, container-closure integrity, preservative effectiveness, extractables and leachables, and product performance.[5]

A sponsor seeking formulation-based differentiation should establish early whether the product can rely on the reference product's clinical data. The greater the difference from conventional Xalatan, the less likely an abbreviated regulatory strategy will be sufficient without additional clinical or bridging evidence.

What commercial opportunities exist in the Xalatan market?

Which companies can compete with Xalatan?

Competition comes from several groups:

1. Generic pharmaceutical manufacturers selling standard latanoprost solutions.
2. Branded ophthalmic companies developing preservative-free glaucoma products.
3. Contract manufacturers with sterile ophthalmic filling capabilities.
4. Packaging and device companies supplying preservative-free multidose systems.
5. Combination-product developers targeting adherence and reduced dosing frequency.

The conventional generic segment is price sensitive. A new entrant with the same BAK-containing solution is likely to compete on manufacturing cost, supply reliability, wholesaler access, and payer contracts.

A differentiated formulation can compete on total treatment value rather than unit price. The most credible targets are patients who experience intolerance, use several preserved ophthalmic products, or have ocular-surface disease.

What revenue exposure does Xalatan have?

Xalatan itself is a mature product with substantial historical commercial exposure, but current revenue is diluted by generic substitution. The financial opportunity is more likely to arise from:

• A premium preservative-free product.
• A fixed-dose combination.
• Licensing a container or delivery platform.
• Supplying excipients or sterile-fill capacity.
• Entering markets with limited access to temperature-controlled distribution.
• Replacing older BAK-containing products in specialty ophthalmology channels.

Revenue potential depends on reimbursement, formulary placement, physician adoption, and whether the product demonstrates a meaningful advantage over lower-priced generic latanoprost.

How does Xalatan compare with preservative-free glaucoma competitors?

Attribute	Conventional Xalatan-type product	Preservative-free latanoprost	Preservative-free fixed-dose product
Preservative	Usually BAK	None	None or alternative system
Packaging	Multidose bottle	Unit-dose or specialized multidose	Specialized multidose or unit-dose
Manufacturing cost	Low to moderate	Higher	Higher
Ocular-surface positioning	Limited	Stronger	Stronger if supported by clinical data
Generic substitution risk	High	Moderate initially	Lower if protected and differentiated
IP potential	Low for basic formulation	Moderate to high	High if combination or device claims are novel
Regulatory complexity	Relatively low	Moderate to high	High
Pricing power	Low	Moderate	Potentially high

The strategic question is whether the sponsor is building a low-cost generic or a premium ophthalmic product. The same excipient decision produces different economics in each model.

What manufacturing and intellectual-property barriers affect new entrants?

Sterile ophthalmic manufacturing is a meaningful barrier even when the formulation is simple. Key requirements include validated sterilization or aseptic processing, low particulate levels, robust container-closure integrity, preservative effectiveness where applicable, and consistent fill volume.

Manufacturing barriers

• Aseptic filling capacity for low-viscosity ophthalmic solutions.
• Reliable supply of ophthalmic-grade excipients.
• Low-bioburden water systems.
• Container-closure integrity testing.
• Drop-size and dose-delivery consistency.
• Stability under refrigerated and room-temperature conditions.
• Control of latanoprost degradation products.
• Compliance with current good manufacturing practice requirements.

IP barriers

A new product must avoid claims covering:

• Specific preservative-free container systems.
• Metered-dose ophthalmic dispensers.
• Protected formulation ranges.
• Combination therapies.
• Manufacturing processes.
• Device and container interfaces.

Freedom-to-operate analysis should include issued patents, pending applications, continuations, foreign counterparts, and patent-term adjustments. It should also examine patents held by packaging companies, not only pharmaceutical sponsors.

When could generic or differentiated entry occur?

Standard generic entry has already occurred. Future entry depends on the product category.

Entry type	Timing profile	Principal barrier
Conventional BAK-containing latanoprost	Immediate market entry possible	Price competition and supply economics
Preservative-free unit-dose product	Commercial launch after formulation and packaging development	Cost, usability, and regulatory evidence
Preservative-free multidose product	Longer development cycle	Device performance and microbial protection
Fixed-dose latanoprost combination	Longer development cycle	Clinical, CMC, and combination-product requirements
Novel delivery technology	Longest cycle	Device validation, clinical evidence, and patent clearance

A company that enters with the conventional solution should expect rapid price erosion. A company that enters with a differentiated excipient or device strategy should budget for a longer development cycle but may obtain stronger pricing and patent protection.

What licensing opportunities exist for Xalatan-related excipient strategies?

The most practical licensing targets are platform technologies rather than the expired Xalatan formulation itself. Potential deal structures include:

• Licensing a preservative-free multidose container.
• Acquiring regional rights to a branded generic latanoprost product.
• Co-developing a fixed-dose latanoprost combination.
• Licensing an ophthalmic sterile-fill process.
• Partnering with an excipient supplier on a proprietary preservative or buffer system.
• Granting manufacturing rights to a contract development and manufacturing organization.
• Licensing formulation patents for emerging markets with storage constraints.

A strong deal should define ownership of formulation improvements, device modifications, regulatory filings, manufacturing know-how, and patent prosecution rights. The agreement should also allocate responsibility for product complaints, sterility failures, recalls, and post-approval changes.

Key Takeaways

• Xalatan is a BAK-preserved, phosphate-buffered latanoprost ophthalmic solution.
• The basic Xalatan formulation has limited current patent value because compound and product exclusivity have expired.
• Standard generic latanoprost is a low-margin, price-driven opportunity.
• Preservative-free latanoprost offers the clearest formulation-based commercial differentiation.
• Preservative-free multidose systems have greater value than unit-dose products but require more complex microbial and device validation.
• Excipient changes can create regulatory differentiation only when they produce meaningful stability, tolerability, or delivery benefits.
• New patents should focus on formulation ranges, packaging, delivery systems, manufacturing processes, and fixed-dose combinations.
• The strongest commercial strategy combines an ocular-surface benefit with reliable sterile manufacturing and defensible container or device IP.

FAQs

Is benzalkonium chloride required in latanoprost ophthalmic solution?

No. BAK is used in conventional multidose products such as Xalatan, but preservative-free and alternative-preservative presentations are possible if they meet sterility, stability, delivery, and regulatory requirements.

Can a company obtain a new patent for preservative-free latanoprost?

Yes, if the product contains a novel and non-obvious formulation, container, delivery system, manufacturing process, or use. A generic claim to "preservative-free latanoprost" alone may face substantial patentability challenges.

Is preservative-free latanoprost automatically clinically superior to Xalatan?

No. It may improve tolerability for some patients, particularly those exposed to multiple preserved ophthalmic products, but superiority requires appropriate comparative clinical or ocular-surface evidence.

What is the main commercial risk for a new generic latanoprost product?

The principal risk is rapid price erosion caused by multiple approved suppliers. Supply reliability, low manufacturing cost, channel access, and product quality become more important than patent exclusivity.

Which excipient change is most likely to create commercial value?

Removing BAK or replacing the conventional multidose package with a validated preservative-free delivery system has the greatest potential. Buffer or tonicity changes alone are less likely to support premium pricing without measurable clinical or stability benefits.

References

1. DailyMed. (2024). Xalatan- latanoprost ophthalmic solution prescribing information. U.S. National Library of Medicine.

2. European Medicines Agency. (2022). Guideline on quality requirements for medicinal products containing a device component. European Medicines Agency.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). FDA.

5. U.S. Food and Drug Administration. (2023). Quality considerations for topical ophthalmic drug products. FDA.

6. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. ICH.

7. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Ophthalmic products and sterile drug product chapters. USP.